This is an old revision of this page, as edited by BogBot (talk | contribs) at 21:16, 30 August 2011 (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 21:16, 30 August 2011 by BogBot (talk | contribs) (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundClinical data | |
---|---|
AHFS/Drugs.com | Monograph |
MedlinePlus | a682860 |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H44N14O8 |
Molar mass | 668.706 g/mol g·mol |
InChI
|
Capreomycin is a peptide antibiotic, commonly grouped with the aminoglycosides, which is given in combination with other antibiotics for tuberculosis. Adverse effects include nephrotoxicity and 8th cranial nerve toxicity.
The drug should not be given with streptomycin or other drugs that may damage the 8th nerve.
It is a cyclic peptide. Capreomycin is administered intramuscularly and shows bacteriostatic activity.
References
- PMID 16857584
Antimycobacterials, including tuberculosis treatment and leprostatic agents (J04) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Nucleic acid inhibitor |
| ||||||||
Protein synthesis inhibitor |
| ||||||||
Cell envelope antibiotic |
| ||||||||
Other/unknown | |||||||||
Combinations | |||||||||
|
This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |